Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 7.2% – Here’s Why

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares were down 7.2% on Monday . The stock traded as low as $0.73 and last traded at $0.74. Approximately 2,468,358 shares traded hands during trading, an increase of 966% from the average daily volume of 231,637 shares. The stock had previously closed at $0.80.

Hepion Pharmaceuticals Price Performance

The firm has a market cap of $103,138.00, a PE ratio of -0.17 and a beta of 1.62. The business’s fifty day moving average is $8.33 and its 200-day moving average is $23.30.

Institutional Investors Weigh In On Hepion Pharmaceuticals

An institutional investor recently bought a new position in Hepion Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals at the end of the most recent quarter. Institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.